Navigation Links
Benign or cancerous?
Date:11/11/2008

Research into a cancer that is on the rise in the UK is to be presented at the University of Leicester.

It will discuss new studies at Leicester into the differences between benign and cancerous moles.

Postgraduate researcher Dr Philip Da Forno of the Department of Cancer Studies and Molecular Studies will describe new advances in the fight against malignant melanoma at a Doctoral Inaugural Lecture to be given on 12 November.

Dr Da Forno has investigated the expression of a particular protein in the progress of the disease and the molecular differences between types of 'Spitzoid' melanocytic tumours and malignant melanoma

He said: "Malignant melanoma is a common cancer of the skin that is increasing in incidence in the United Kingdom. Early cancers are easily cured but once the disease has spread to other sites in the body, there is no effective treatment and the outcome is often fatal.

"I will discuss our current understanding of how melanocytic lesions progress from benign tumours or small, easily curable cancers, to advanced, frequently fatal cancers. This will include a description of my investigation into expression of the protein Wnt5a during tumour progression and its effect on patient survival."

The diagnosis of melanoma is achieved via microscopic examination of lesional tissue. In the majority of cases this is straightforward and, having made the diagnosis of malignancy, the histopathologist applies a number of criteria to determine which tumours are likely to have been cured by excision and which are at risk of spreading elsewhere and killing the patient. Unfortunately, the behaviour of the tumour cannot always be predicted with accuracy and some patients with seemingly indolent tumours have rapidly progressive disease.

In some instances histological assessment is complicated further by a difficulty in determining whether the tumour is a benign 'mole' or a malignant melanoma. Nowhere i
'/>"/>

Contact: Dr Philip Da Forno
pddf1@le.ac.uk
University of Leicester
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
2. MDCT, virtual gastroscopy and MPR images differentiate malignant and benign gastric ulcers
3. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
4. Virtual biopsy can tell whether colon polyp is benign without removal, Mayo researchers say
5. Incidental adrenal masses commonly seen on CT are usually benign; no follow-up needed
6. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. 6-month follow-up diagnostic mammograms recommended for women with probably benign lesions
8. Estrogen therapy increases benign breast disease risk
9. Estrogen Supplements May Raise Odds of Benign Breast Disease
10. COX-2 expression is marker for cancer development in some benign breast biopsies
11. Malignant tumor or benign cyst?

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)... promotes self-assurance, research finds , ...r may have been right when she told you to sit up ...could make you feel more confident about your thou...p straight gives a good impression to other people...chology professor at Ohio State University, said i...
(Date:11/8/2009)...ire-USNewswire/ -- Speaker Nancy Pelosi and Democr... House passage of H.R. 3962, the Affordable Health...of 220 to 215. Below are the Speaker,s opening re...ceived a call from the President of the United Sta...ctory for the American people. I thank the Preside...
(Date:11/8/2009)...drying of biopharmaceuticals to be available at th... , Toronto, ON (PRWEB) Nov... of Therapure Biopharma Inc. today announced that ...le pharmaceutical grade freeze dryer and expects t...ion) available for contract manufacturing of bioph...
(Date:11/8/2009)... the battle is won," said Dr. Charmaine Yoest. ,...In a vote of 240-194, the Stupak-Ellsworth-Pitts-K...bit abortion mandates and funding in HR 3962 passe...ife Action President and CEO Dr. Charmaine Yoest s...or the pro-life Americans across this country who ...
(Date:11/8/2009)... H.R. 3961 to Secure the Stability of Medicare ,...tement Attributable to: J. James Rohack, M.D., Pre... http://www.newscom.com/cgi-bin/prnh/20081209/AM...House health reform bill, which will help improve ...calls for swift passage of H.R. 3961 to secure the...
Breaking Medicine News(10 mins):Health News:Good Posture May Inspire Confidence 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2
...ame of a Class 10 correspondence course student in...iled to do, an official said Saturday//. The ...d 22 students of various private and government hi...at had three others with the same score. The boy h...
...sights about how a bacterium uses different recept...a are sensitive to minute changes in environments ...of 1 drop in a pool of 1,000 drops. New Corn...perative lattice on a bacterium's surface to ampli...
... essential for proper embryo development and disor...h defects such as cleft palate, spina bifida, repo...ffort of the University of Colorado, Health Scienc...Critical for Downregulation of E-Cadherin During M...
...announced a warning on the usage of Triaminic vapo...serious effects //they could have if accidentally ...h authorities have explained that life-threatening...ised as a cough suppressant for kids 2 years of ag...
...fter eating (traditionally called European siesta)... happening due to changes in glucose levels//. ...y in humans and as well as in animals become switc...sed from the neurons, whose action is focused on t...
...er treatment drug has proved so well in the drug t...ght be made //available to patients in the late st...the regulators. It is speculated that Europe... claim that unlike Roche's $1.8bn-a-year drug, Her...
Other Medicine News:Health News:Study Highlights How Bacteria Respond To Changes In Environment 2Health News:GSK’s New Anticancer Drug A Huge Success In Drug trail 2
(Date:11/6/2009)...TA, Nov. 6 GeoVax Labs,...e Company"), an Atlanta-based, biopharmaceutical c...ed by HIV-1 (Human Immunodeficiency Virus) and oth...arter 2009 financial results and provided an opera...ent and Chief Executive Officer commented, "We are...
(Date:11/6/2009)...IEGO, Nov. 6 California American W...s "No Drugs Down the Drain" week for its San Diego...n sponsored by public and private agencies alike t...l pollution in our source water supplies. ,, Ca...rs are encouraged to drop off expired or unwanted ...
(Date:11/5/2009)...IEGO, Nov. 5 Althea Technologies,...acturing services for biopharmaceutical products a...velopment to the company,s platform of services, w...ames Matsuura, Director of Formulation Development...ation and analytical scientists, along with new la...
Breaking Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 1Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 2Hutchinson Center scientists net 2416 7 million for stem cell research 59136 1Hutchinson Center scientists net 2416 7 million for stem cell research 59136 2Elderly immune system needs a boost 59134 1Elderly immune system needs a boost 59134 2
... 12 Boston,Scientific Corporation (NYSE: BSX ) t...7,500 patients from its TAXUS ARRIVE 1 and 2 regis...ce of the TAXUS(R) Express2(TM),Paclitaxel-Eluting...,two-year pooled ARRIVE data showed that the TAXUS...h diabetes as effectively as in patients without,d...
...entific,Corporation (NYSE: BSX ) today announced ...ss announcements at the Cardiovascular Research Fo...rdiovascular Therapeutics (TCT),scientific symposi..., D.C., Boston Scientific will be announcing a wi...R) Express2(TM) and second-generation TAXUS(R),Lib...
Other Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
Giardia lamblia II EIA
Medicine Products: